

Box Seq # GP 1635

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 25 1999

Applicants: Elazar Rabbani et al.

Serial No. 08/978,633

Filed: November 25, 1997

Title: NOVEL PROPERTY EFFECTING  
AND/OR PROPERTY EXHIBITING  
COMPOSITIONS FOR THERAPEUTIC  
AND DIAGNOSTIC USE

Group Art Unit: 1635

Examiner: Mary M. Schmidt



527 Madison Avenue, 9th Floor  
New York, New York 10022  
August 16, 1999

FILED VIA FIRST CLASS MAIL

Honorable Commissioner  
of Patents and Trademarks  
Washington, D.C. 20231

Attention: Box Sequence

COMMUNICATION DIRECTED TO NOTICE  
TO COMPLY WITH SEQUENCE RULES


Dear Sirs:

This Communication is directed to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures referenced in the Office Action issued February 16, 1999 which issued in connection with the instant application. While a copy of the Notice was not attached to Applicants' copy of the aforementioned Office Action, Applicants hereby submit the following documents or items:

1. an initial paper copy of the Sequence Listing;
2. an Amendment directing entry of the Sequence Listing into the specification;
3. a computer readable form (CFR) copy of the substitute Sequence Listing; and

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks Washington, D.C. 20231

  
Ronald C. Fedus  
Reg. No. 32,567

AUG 16 99

Date

Elazar Rabbani et al.  
Serial No. 08/978,633  
Filed: November 25, 1997  
Page 2 (Communication Directed to Notice to Comply With Sequence Rules -  
August 16, 1999)

4. a Declaration Under 37 C.F.R. §1.821(g) attesting that the content of the paper copy and computer readable copy are the same and include no new matter.

No fee is believed due in connection with this Communication or the documents or items submitted herewith other than the fee payment authorized in the Request For an Extension Of Time (Three Months Under 37 C.F.R. §1.136(a)). If any other fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
(212) 583-0100

LC/USProsecution/Enz53(D1)/communication.re.sequence rules081699.enz53(D1)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Elazar Rabbani et al.

Serial No. 08/978,633 Group Art Unit: 1635

Filed: November 25, 1997 Examiner: Mary M. Schmidt

Title: NON-IONICALLY BOUND CONSTRUCTS AND COMPOSITIONS  
AND KITS COMPRISING DOMAINS



**FILED BY FIRST CLASS MAIL**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D. C. 20231

Sir:

Transmitted herewith is an Amendment Under 37 C.F.R. § 1.115 (In Response  
To The February 16, 1999 Office Action) in the above-identified patent application.

The fee\* has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	58	Minus	81	0=	X\$9.00	\$ 0
Indep	7	Minus	7	0=	X\$39.00	\$ 0
( )	First Presentation of Multiple Dependent Claims				\$130.00	\$
	TOTAL ADDITIONAL FEE					\$ 0 13

\*Small entity status was previously established in this application and is still applicable.

- ( ) Charge Deposit Account No. 05-1135 in the amount of \$ \_\_\_\_\_
- ( ) A check in the amount of \$ \_\_\_\_\_ is attached.
- (X) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135 any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims and any patent application processing fees under 37 C.F.R. §1.17.

Copies are being provided in triplicate.

Also enclosed: Request For An Extension Of Time (Three Months); Amendment IN Connection with Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures Under 37 CFR §§1.821-I.825; Communication Directed To Notice To Comply With Sequence Rules; Initial Paper Copy of the Sequence Listing; Computer Readable Form copy of the Sequence Listing; Declaration Under 37 CFR §1.821(g)

Respectfully submitted,

Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

**FIRST CLASS CERTIFICATE**

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks Washington, D.C. 20231

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
Tel. (212) 583-0100  
Attorney's Docket No.: Enz-53(D1)  
lcTransmittalAmendment.ENZ53.D1.081699

